Sun, Sep 21, 2014, 5:54 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Amarin Corporation plc Message Board

  • mymandon mymandon Mar 3, 2013 10:40 PM Flag

    Will Insurance companies support putting most CV patients on Vascepa?

    Insurance companies should want majority of CV patients on Vascepa. The prevailing wisdom is that insurance companies want to avoid putting patients on Vascepa to save money on drug benefits. I take issue with this thinking and would argue that- based on the known benefits of Vascepa (MARINE and ANCHOR) and to improve LDL and other key biomarkers of CV disease to even greater extent in combination with statins (MARINE, ANCHOR and AMR102) and the potential prevent cardiovascular events (REDUCE-IT) ment Insuance companies will push doctors to put as many CV patients and statin users on Vascepa as soon as possible. They would actually save money by preventing future costs using evidence-based medicine to employ "the conscientious, explicit and judicious use of current best evidence in making decisions about the care of individual patients." By using "mathematical estimates of the risk of benefit and harm, derived from high-quality research on population samples, to inform clinical decision-making in the diagnosis, investigation or management of individual patients" they could benefit both patients and the bottom line. An actuarial analyses would be needed, but with the high cost of management of CV events and the fact that Vascepa adds no additional risk (and provides potentially a sizeable benefit) may be a win-win for both patients and insurance companies to start vast majority of patients at risk of CV event (previous MI, age over 55, Diabetes, etc) on Vascepa as preventative treatment.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Don, Sorry to disillusion you. I am a practicing physician and a former pharmacist. The insurance companies have NO interest in providing better health care for the most part. They are interested in saving money THIS year, not imn preventing illness next year or in the distant future. Their bottom line is what is important. If they can save money THIS year by pushing physicians to prescribe a less expensive medication than one the pjhysician is using for a specific patient, they will do it. A physician often has to fight them to allow payment for the medication he/she wants to use for a patient because the Insurance Company "says" that the "medications are equal". Even if the MD thinks otherwise. Next year is a different year - new premiums, new patients. Preventive care - use of a more expensive medication or other treatment to prevent FUTURE illnesses does not benefit their bottom line TODAY. Next year they will deal with the economics of next year and so forth. Their propaganda would lead you to think otherwise, but what I am telling you is factual. Unfortunate but true. Of course there could be a miracle and insurance companies could send out an information letter to MDs explaining that the more expensive Vasepa is better than Lovaza, but don't count on it. ZB D

    • It makes too much sense when you think about it, forward thinking, rational, smart, wise. Let's hope the establishment smartens up.

 
AMRN
1.30-0.05(-3.70%)Sep 19 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.